The capacity of monoclonal antibodies to protect mice passively against yellow fever (YF) virus infection was investigated. Both neutralizing (54K-specific) and nonneutralizing (54K-and 48K-specific) antibodies protected mice against challenge with the RMP substrain of YF virus. Average survival times of mice inoculated intracerebrally with a standard lethal dose of YF virus differed according to the strain used: thus mice inoculated with the most neurovirulent viruses, FNV and Asibi, survived for 6-50 and 7.65 days respectively, and those with RMP virus survived for 15.75 days. The capacity of antibodies to protect mice passively against virus challenge was directly related to virus neurovirulence. Possible mechanisms and the significance of protection by antibodies against non-structural proteins that do not mediate neutralization, are discussed.
Both polyclonal and monoclonal antibodies may protect mice passively against lethal virus infection (Rabinowitz & Adler, 1973; Griffin & Johnson, 1977; Dix et al., 1981 ; Schmaljohn et al., 1982; Mathews & Roehrig, 1982; Talbot et al., 1984; Boere et al., i985; Hunt & Roehrig, 1985) . Frequently, protection is associated with biological characteristics like neutralization and haemagglutination inhibition. The roles of neutralizing and non-neutralizing antibodies in flavivirus immunity are not clear, and seem to be highly complex because of antigenic crossreactions between different viruses (for review, see Porterfield, 1980) . We have characterized monoclonal antibodies (MAb) against a number of YF virus strains (Gould et al., 1985a) which are specific either for the viral envelope protein (54K) or the non-structural protein (48K). Here we describe their ability to protect mice against an intracerebral challenge with YF viruses of differing neurovirulence.
The strains of YF virus used were as follows: French neurotropic vaccine (FNV), Asibi (AS), virus which is the parent of all vaccine strains except FNV, three derivatives of the 17D vaccine (S 17D, W 17D and RMP), and the Brazilian derivative of the 17DD vaccine (B 17DD) (Gould et al., 1985a) . Monoclonal antibodies were prepared against either the 17D and FNV strains or AS virus as described previously (Gould et al., 1985a) . Antibodies, as mouse ascitic fluids, with molecular specificity for either the 54K protein or the 48K protein of W17D were used. By indirect immunofluorescence titrations using W 17D-infected Vero cells all MAb had titres of at least 104 and the concentration of IgG in ascitic fluid was between 1.5 and 2 mg/ml. For passive immunization young adult female mice (strain TO, outbred; Tuck and Sons, Battlesbridge, Essex, U.K.) were inoculated intraperitoneal!y with 0.1 ml of undiluted mouse ascitic fluid containing MAb, Groups of eight mice were inoculated intracerebrally 24 h later with 100 LDso of the appropriate YF virus. The mice were monitored daily. In preliminary experiments, each virus was titrated by intracerebral inoculation in groups of young adult mice using serial tenfold dilutions of input virus (0.02 ml/mouse) and average survival times (AST) were estimated. Virus (4) 24 (7) 24 (4) 825 IgG2a 24 (1) 19 (0) 17 (1) 18 (1) 868 IgG2a 18 (1) 24 (0) 16 (1) 12 (1) 813 IgG2a 0 (1) NT~ (0) NT (1) 18 (0) 
IgG3 15 (0) 18 (0) 7 (0) 18 (0) * AST (days) of mice receiving normal ascitic fluid in lieu of antibody. "t" In all columns in Tables 1 and 2 figures denote numbers of survivors out of 24 mice inoculated. Numbers in parentheses are neutralization indices (log10 reduction of infectivity using MAb at 1/20 dilution; see Buckley & Gould, 1985) .
NT, Not tested. infectivity was titrated using Vero cells (Chanas et al., 1982) . For indirect immunofluorescence microscopy Vero cells on coverslips were infected with YF virus and after incubation at 37 °C for 3 days were either washed in phosphate-buffered saline and tested directly for cell surface antigen or were fixed in cold acetone. The biotin-streptavidin method was used (Gould et al., 1985b) . Mice were inoculated intraperitoneally with 54K-specific MAb, as ascitic fluid, and then challenged intracerebrally 24 h later with 100 LDs0 per mouse of an appropriate strain of YF virus. Each experiment was repeated three times. Both FNV and AS viruses killed all mice irrespective of which 54K-specific MAb was used (results not presented). The AST of mice injected with FNV and AS virus and treated with control ascitic fluid were 6.50 + 0.27 and 7.60 + 0.26 days respectively. In contrast, all but one of the 54K-specific antibodies conferred immunity (>~50~o survivors) when RMP virus was used for challenge (AST 15.30 + 1.60 days) ( Similar experiments were then performed with 48K-specific MAb (Table 2) . Only results obtained with RMP virus are shown since 48K-specific MAb neither neutralized infectivity nor protected mice when any other viruses were used for challenge. Eight of the 48K-specific MAb showed at least 50~ protection of the mice against challenge with RMP virus.
Two MAb with very different titres in neutralization tests but with similar titres by immunofluorescence titration were compared in mouse protection experiments. Serial dilutions of MAb 864 and 427 were inoculated intraperitoneally into groups of eight mice which were challenged intracerebrally 24 h later with serial dilutions of RMP virus in chequerboard fashion. There was no significant difference in titre between the antibodies, both showing complete protection up to 1/25 and 50~ protection at a dilution of 1/125.
In view of the large difference in AST of mice after intracerebral challenge with either FNV or RMP virus, the abilities of these two viruses to multiply in mouse brains were compared. Fig.  1 shows that the infectivity of FNV increased rapidly whereas that of RMP was significantly lower and had started to decrease by day 8. In contrast the titres of FNV or RMP virus in brains of newborn mice were always in excess of 107 p.f.u./ml when mice became moribund (6 and 7 days respectively).
Immunofluorescence tests were performed using MAb with both fixed and unfixed virusinfected Vero cells. Fig. 2(a) illustrates the pattern of cytoplasmic fluorescence seen when acetone-fixed FNV-infected Vero cells were tested using MAb 979 (48K-specific). A bright zone of perinuclear fluorescence was observed. When the same antibody was tested using unfixed infected cells, which do not permit antibody penetration, small fluorescent areas were barely visible on the plasma membrane (Fig. 2b) . No fluorescent particles equivalent to released virions (Gould et al., 1985 a), were seen. There was no fluorescence on the surface of uninfected cells.
Our results show that MAb against both the 54K structural envelope protein and the 48K nonstructural protein of YF virus can protect mice against infection. The ability of antibody to protect mice passively, however, seems to depend on the degree of neurovirulence of the virus for mice. Overall, there was no clear-cut relationship between the ability of MAb to neutralize virus infectivity in vitro and to protect mice in vivo. We showed previously (Buckley & Gould, 1985) that with 54K-specific MAb, neutralization of YF virus infectivity depended upon the strain chosen although there was no correlation with virulence.
There are several possible ways in which MAb specific for the 54K envelope protein might protect mice; binding of MAb to the viral surface could either act as an impediment to the attachment of virus to the target cells, or block the uncoating or aggregation of input and released virus particles. Alternatively, conformational alterations of viral proteins induced by attachment of antibody, as was reported for Sindbis virus (Clegg et al., 1983) , could reduce the efficiency of viral infection. Failure of antibodies to protect mice against high virulence strains possibly reflects an extremely high rate of virus replication as seen with FNV virus; even small quantities of unneutralized virus would rapidly attain high titres. Different antibody binding affinities cannot explain the in vivo differences since in ELISA tests the antibody-binding profiles of these viruses are almost identical (Cammack & Gould, 1986) .
The mechanism by which the 48K-specific MAb protected against RMP virus is less obvious. Antibodies might attach to the surface of infected brain cells and impair virus spread, or attach to antigen-containing cytoplasmic and plasma membrane fragments released, with attached virus particles, during the process of exvagination (Westaway, 1980) . Alternatively, the presence of 48K protein at the cell surface might attract T cells. Finally, macrophages or complement might recognize attached antibody and destroy the virus. The slow replication and prolonged AST, after infection with the RMP variant, combined with any of the above circumstances, should provide sufficient time for the generation of immune responses and thus recovery of infected mice.
It is perhaps worth considering the extent to which flavivirus 48K non-structural proteins are related antigenically. If equivalent protection can be demonstrated then antigenic crossreactivity should be taken into account when designing synthetic vaccines.
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